Skip to content
The Policy VaultThe Policy Vault

sofosbuvir/velpatasvirMedica

Chronic Hepatitis C Virus (HCV) Genotype 1, 2, 3, 4, 5, or 6, decompensated cirrhosis (Child-Pugh B or C), prior null responder, prior partial responder, and prior relapser to sofosbuvir/velpatasvir or Vosevi

Initial criteria

  • age ≥ 3 years
  • Patient has decompensated cirrhosis (Child-Pugh B or C)
  • Previously treated with sofosbuvir/velpatasvir or Vosevi
  • Medication will be prescribed in combination with ribavirin
  • Prescribed by or in consultation with a gastroenterologist, hepatologist, infectious diseases physician, or liver transplant physician

Approval duration

24 weeks